COMMD2: A Potential Drug Target for Neurodegenerative Diseases

Target Name: COMMD2

NCBI ID: G51122

COMMD2

COMMD2: A Potential Drug Target for Neurodegenerative Diseases

COMMD2, also known as COMMD2-cation form, is a protein that is expressed in various tissues of the body, including the brain, heart, and skeletal muscles. It is a key regulator of the myelin sheath that surrounds nerve cells, and is involved in the development and maintenance of neural circuits.

COMMD2 is a transmembrane protein that consists of four intracellular domains: a N-terminal transmembrane domain, a T-terminal intracellular domain, a middlemost intercellular domain, and a C-terminal intracellular domain. The N-terminal and T-terminal domains are involved in the formation of the transmembrane region, while the middlemost and C-terminal domains interact with other proteins within the cell.

COMMD2 is a protein that has been identified as a potential drug target in the field of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. These conditions are characterized by the progressive loss of nerve cells and the formation of aggregates of neurotransmitters , such as dopamine and beta-amyloid, which can cause the symptoms associated with these conditions.

COMMD2 has been shown to play a role in the development and progression of these neurodegenerative diseases. Studies have shown that individuals with certain genetic mutations, such as those carrying the APTN3 gene, are at an increased risk of developing Alzheimer's disease. Additionally, individuals with Certain environmental factors, such as exposure to certain toxins or radiation, have also been shown to be at an increased risk of developing these conditions.

COMMD2 has also been shown to be involved in the development and progression of other neurodegenerative diseases, such as Parkinson's disease and Huntington's disease. Studies have shown that individuals with certain genetic mutations, such as those carrying the SNCA gene, are at an increased risk of developing Parkinson's disease, while individuals with certain environmental factors, such as exposure to certain toxins or radiation, have also been shown to be at an increased risk of developing Huntington's disease.

In addition to its involvement in neurodegenerative diseases, COMMD2 has also been shown to play a role in the development and progression of certain neurological conditions, such as multiple sclerosis and amyotrophic lateral sclerosis (ALS). Studies have shown that individuals with certain genetic mutations, such as those carrying the NLRP1 gene, are at an increased risk of developing multiple sclerosis, while individuals with certain environmental factors, such as exposure to certain toxins or radiation, have also been shown to be at an increased risk of developing ALS.

COMMD2 is a protein that has been shown to play a role in the development and progression of a wide range of neurodegenerative diseases, and is therefore an attractive target for drug development. Studies have shown that COMMD2 can be effectively targeted with small molecules, such as those that can inhibit its activity or modulate its expression levels.

COMMD2 is a protein that is expressed in various tissues of the body, and its function is to regulate the myelin sheath that surrounds nerve cells. It is a key regulator of the neural circuits, and is involved in the development and maintenance of these circuits. Its expression is regulated by various factors, including its own intracellular signaling pathways, as well as the signaling pathways of other proteins within the cell.

COMMD2 is a protein that has been identified as a potential drug target in the field of neurodegenerative diseases. Its involvement in the development and progression of these conditions makes it an attractive target for drug development, and its transmembrane structure and various intracellular domains make it a

Protein Name: COMM Domain Containing 2

Functions: May modulate activity of cullin-RING E3 ubiquitin ligase (CRL) complexes (PubMed:21778237). May down-regulate activation of NF-kappa-B (PubMed:15799966)

The "COMMD2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about COMMD2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets